Page 10 - Mel Sorensen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mel sorensen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mel Sorensen Today - Breaking & Trending Today

Galera Appoints Mark J. Bachle - GuruFocus.com

GuruFocus Article or News written by Marketwired and the topic is about: ....

United States , Christopher Degnan , Mel Sorensen , Markj Bachleda , Zara Lockshin , Jennifer Evans Stacey , Bristol Myers Squibb , William Windham , University Of California , Princeton University , Thomas Jefferson University , Columbia University , Exchange Commission , Endo International , Antares Pharma , Galera Therapeutics Inc , University Of Illinois At Chicago , Wistar Institute , Auxilium Pharmaceuticals Inc , University Of Pennsylvania Law School , Chief Commercial Officer , Chief Legal , Compliance Officer , Vice President , Unit Head , Juno Therapeutics ,

New Rule Forces Washington Residents With Good Credit to Pay More for Insurance

Washington residents with good credit scores are facing sticker shock when their car or home insurance comes up . ....

Thurston County , United States , Mel Sorensen , Mike Kreidler , Jeremy Lott , Andy Weeda , Office Of The Insurance , A Federal Trade Commission , Center Square , Thurston County Superior Court On , Washington Legislature , Washington Insurance Commissioner Mike Kreidler , Insurance Commissioner , Federal Trade Commission , Professional Insurance Agents , Independent Insurance Agents , Thurston County Superior Court , Insurance Company , Insurance Policy , The Epoch Times ,

Science Translational Medicine Article Shows Galera's Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors
Describes mechanism which sensitizes cancer cells to radiotherapy
Supports recent results showing a near doubling of median overall survival observed in patients with pancreatic cancer by combining Galera’s dismutase mimetic with radiation therapy
MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that
Science Translational Medicine has published a foundational preclinical article describing the synergy of avasopasem manganese, one of the Company’s selective dismutase mimetics, with high fraction dose radiotherapy, such as stereotactic body radiation therapy (SBRT) or stereotactic ablative ra ....

United States , Christopher Degnan , Mel Sorensen , Zara Lockshin , William Windham , Exchange Commission , University Of Texas Southwestern , University Of Iowa , Galera Therapeutics Inc , Galera Therapeutics , Science Translational Medicine , Texas Southwestern , Fast Track , Breakthrough Therapy , Private Securities Litigation Reform Act , Breakthrough Therapy Designation , Fast Track Designation , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டோபர் டெஞன் , மெல் சோரன்சென் , ஸ்யார லாக்ஷின் , வில்லியம் வின்ட்ஹாம் , பரிமாற்றம் தரகு , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் தென்மேற்கு , பல்கலைக்கழகம் ஆஃப் ஐயுவா ,

Why Galera Therapeutics Stock is Trading Higher Today

Galera Therapeutics (NASDAQ:GRTX) shares are trading higher after the company announced updated data from its randomized, multicenter, placebo-controlled trial in patients with pancreatic cancer.
The data from this trial continue to impress, showing consistent and durable benefits across multiple measures, including the most important for the patient, overall survival, said Mel Sorensen, M.D., President and CEO of Galera.
Galera Therapeutics Inc is a biopharmaceutical company focused on developing therapeutics that have the potential to transform radiotherapy in cancer.
The stock was trading 23.45% higher at $8.16. The stock has a 52-week high of $15 and a 52-week low of $6.15.
For the latest in financial news, exclusive stories, memes follow ....

Mel Sorensen , Galera Therapeutics Inc , Galera Therapeutics , Therapeutics Inc , மெல் சோரன்சென் , கலேற சிகிச்சை இன்க் , கலேற சிகிச்சை , சிகிச்சை இன்க் ,